Applied dna submits request for emergency use authorization to fda for linea™ sars-cov-2 mutation panel

Stony brook, n.y.--(business wire)---- $apdn #covid19--eua request for rapid alternative to ngs to identify mutations that may negatively impact efficacy of anti-sars-cov-2 monoclonal antibody treatments.
APDN Ratings Summary
APDN Quant Ranking